{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:38:36Z","timestamp":1790883516630,"version":"4.1.0"},"reference-count":93,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,22]],"date-time":"2006-01-22T00:00:00Z","timestamp":1137888000000},"content-version":"vor","delay-in-days":82,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:p>High\u2010risk human papillomaviruses (HR\u2010HPVs) are one of the most devastating oncogenic viruses worldwide and have been causally linked with the development of human cervical cancer. Several prophylactic and therapeutic clinical HPV vaccine trials are in progress. Although prophylactic vaccines are useful in preventing the incidence of cervical cancer, the elimination of existing HPV infections needs to be addressed, because cervical cancer is the leading female cancer in developing countries. Several different and encouraging strategies have been investigated in a preclinical and clinical setting for the treatment and elimination of existing HPV\u2010induced infection. This review summarizes the therapeutic clinical trials and the different preclinical research strategies that are under investigation whereby HR\u2010HPV E6 and E7 oncogenes are delivered in a nucleic acid form, in viral and bacterial vectors, or as peptide\u2010 and protein\u2010based vaccines.<\/jats:p>","DOI":"10.1196\/annals.1352.016","type":"journal-article","created":{"date-parts":[[2005,12,30]],"date-time":"2005-12-30T21:37:40Z","timestamp":1135978660000},"page":"328-343","source":"Crossref","is-referenced-by-count":28,"title":["Strategies for Human Papillomavirus Therapeutic Vaccines and Other Therapies Based on the E6 and E7 Oncogenes"],"prefix":"10.1111","volume":"1056","author":[{"given":"V A","family":"GOVAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.9.690"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.10.021"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2004.03.033"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479"},{"key":"e_1_2_6_6_2","first-page":"598","article-title":"Management of anogenital warts (Condylomata acuminata)","volume":"11","author":"Krogh G.","year":"2001","journal-title":"Eur. J. Dermatol."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00177-0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-4310(00)01685-3"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1543"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-3163-2-3"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/427826"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1260"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.3.3.459"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000163906"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-75-9-2271"},{"key":"e_1_2_6_16_2","unstructured":"Koutsky L.A. 2004. Prophylactic HPVL1 virus\u2010like particle (VLP) vaccines. Abstract number 047. Presented at the 21st International Human Papillomavirus Conference Mexico City Mexico."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70101-7"},{"key":"e_1_2_6_18_2","first-page":"129","article-title":"The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical cancer lesions: consequences for clinical management","volume":"26","author":"Brinkman J.A.","year":"2005","journal-title":"Eur. J. Oncol."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-1601-9_11"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1989.tb08570.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1128\/jvi.63.10.4417-4421.1989","article-title":"The E6 and E7 gene of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes","volume":"63","author":"Munger K.","year":"1989","journal-title":"J. Virol."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.13.4680"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.8.1251"},{"key":"e_1_2_6_24_2","unstructured":"Howley P.M.1996.Papillomavirinae: the viruses and their replication. In Fields Virology 3rd ed. B.N. Fieldset al. Eds.: 2045\u20132073. Lippincott\u2010Raven Publishers. Philadelphia."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1659741"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.12.15.2245"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90384-3"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.19332-0"},{"key":"e_1_2_6_29_2","first-page":"217","article-title":"Immune responses to human papillomaviruses and the prospects for human papillomavirus\u2010specific immunisation","volume":"186","author":"Tindle R.W.","year":"1994","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_2_6_30_2","unstructured":"Tindle R.W.et al.1997.Vaccines against papillomaviruses. In New Generation Vaccines. Vol. 50. 2nd Ed. R.W. Tindle I.H. Frazer A. Levine G. Woodrow X. Kaper & X. Cobon Eds.:769\u2010783. Marcel Decker. New York."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000050044"},{"key":"e_1_2_6_32_2","first-page":"1028","article-title":"Encapsulated plasmid DNA treatment for human papillomavirus 16\u2010associated anal dysplasia: a Phase I study of ZYC101","volume":"8","author":"Klencke B.","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.256"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-365"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000110246.93627.17"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.05.013"},{"key":"e_1_2_6_37_2","first-page":"343","article-title":"Design of a candidate recombinant therapeutic vaccine for cervical cancer","volume":"1","author":"Edwards S.J.","year":"1998","journal-title":"Recent Res. Dev. Biotech. Bioeng."},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00332-2"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.09.006"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00486-2"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0501-4"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230929"},{"key":"e_1_2_6_43_2","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high\u2010grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive","volume":"6","author":"Muderspach L.I.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.10.1.5"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1089\/088282403322017866"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11373-005-0334-y"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/6995"},{"key":"e_1_2_6_48_2","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.4049\/jimmunol.158.8.3635","article-title":"Contribution of CpG motifs to the immunogenicity of DNA vaccines","volume":"158","author":"Klinman D.M.","year":"1997","journal-title":"J. Immunol."},{"key":"e_1_2_6_49_2","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1128\/JVI.72.6.5174-5181.1998","article-title":"DNA immunisation with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination","volume":"72","author":"Rodriguez F.","year":"1998","journal-title":"J. Virol."},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.6.2676-2682.2002"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1122"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2004.01.009"},{"key":"e_1_2_6_53_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role of ribonuclease in the initiation step of RNA interference","volume":"409","author":"Berstein E.","year":"2001","journal-title":"Nature"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra045004"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.10.6066-6069.2003"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205878"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2003.08.004"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1089\/oli.2004.14.239"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt831"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1038"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.11.6545"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5916"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2002.23"},{"key":"e_1_2_6_64_2","first-page":"4599","article-title":"In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes","volume":"55","author":"Tan T.M.","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.3.1189"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00214-1"},{"key":"e_1_2_6_67_2","first-page":"2094","article-title":"Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors","volume":"6","author":"Pavco P.A.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00383.x"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/1439-7633(20010903)2:9<629::AID-CBIC629>3.0.CO;2-3"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(93)81102-6"},{"key":"e_1_2_6_71_2","first-page":"267","article-title":"Ribozyme\u2010mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16","volume":"1","author":"Lu D.","year":"1994","journal-title":"Cancer Gene Ther."},{"key":"e_1_2_6_72_2","first-page":"263","article-title":"Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18","volume":"2","author":"Chen Z.","year":"1995","journal-title":"Cancer Gene Ther."},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050302"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00216-N"},{"key":"e_1_2_6_75_2","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1128\/JVI.72.10.8220-8229.1998","article-title":"Nasal immunisation of mice with human papillomavirus type 16 virus\u2010like particles elicits neutralising antibodies in mucosal secretions","volume":"72","author":"Balmelli C.","year":"1998","journal-title":"J. Virol."},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.172.5.2485-2490.1990"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0600-2"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.60.4.1263-1267.1992"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1997.tb00999.x"},{"key":"e_1_2_6_80_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.11.6471"},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10759"},{"key":"e_1_2_6_82_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0610-0"},{"key":"e_1_2_6_83_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/135965350400900515","article-title":"Superior therapeutic efficacy of alphavirus\u2010mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization","volume":"9","author":"Daemen T.","year":"2004","journal-title":"Antivir. Ther."},{"key":"e_1_2_6_84_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430340252809847"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.6.2888-2894.2000"},{"key":"e_1_2_6_86_2","doi-asserted-by":"publisher","DOI":"10.1089\/104303403769211619"},{"key":"e_1_2_6_87_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.12.2157"},{"key":"e_1_2_6_88_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.051630798"},{"key":"e_1_2_6_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0202-149"},{"key":"e_1_2_6_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(03)00064-9"},{"key":"e_1_2_6_91_2","doi-asserted-by":"crossref","unstructured":"Cui Z.et al.2005. Liposome\u2010polycation\u2010DNA (LPD) particle as a carrier and adjuvant for protein\u2010based vaccines: therapeutic effect against cervical cancer. Cancer Immunol. Immunother. Epub.","DOI":"10.1007\/s00262-005-0685-2"},{"key":"e_1_2_6_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2003.11.009"},{"key":"e_1_2_6_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00086-X"},{"key":"e_1_2_6_94_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0703"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1352.016","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1352.016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T22:48:48Z","timestamp":1695682128000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1352.016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1196\/annals.1352.016"],"URL":"https:\/\/doi.org\/10.1196\/annals.1352.016","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}